Infectologia
M-A | Fluvoxamina no tratamento ambulatorial da COVID-19 para evitar internação.
8 Abr, 2022 | 21:52hComentário: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes
Conteúdos relacionados:
Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Comentário no Twitter
Bayesian SRMA of 3 RCTs showed a high prob (94-98.6%) that fluvoxamine is associated with reduced risk of hospitalization for outpatients with #COVID19, (RR 0.75). @DrEmilyMcD @DrToddLee @simonevigod @AngelaReiersen @boulware_dr https://t.co/ctMKzBDbzP
— JAMA Network Open (@JAMANetworkOpen) April 6, 2022
Estudo randomizado | Entre pacientes com infecção complicada de trato urinário, o uso oral de tebipenem pivoxil hidrobromida foi não inferior ao ertapenem intravenoso e mostrou perfil de segurança similar.
8 Abr, 2022 | 21:50hOral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
For complicated UTI or acute pyelonephritis, oral tebipenem pivoxil hydrobromide noninferior to IV ertapenem and has a similar safety profile. https://t.co/FRDMQOD0Pn pic.twitter.com/GFQz7SlciX
— NEJM (@NEJM) April 6, 2022
Perspectiva | Um roteiro equitativo para acabar com a pandemia de COVID-19.
8 Abr, 2022 | 21:43hAn equitable roadmap for ending the COVID-19 pandemic – Nature Medicine
Comentário no Twitter
A Comment article in @NatureMedicine argues that the COVID-19 pandemic will end only with a renewed focus on equitable distribution of vaccines and therapeutics, responsive public health plans, and policies to protect the vulnerable. https://t.co/2cZShdqnY3
— Nature Portfolio (@NaturePortfolio) April 6, 2022
Perspectiva | Como estudar a COVID longa grave para compreender os distúrbios pós-infecciosos além da COVID-19.
8 Abr, 2022 | 21:42hStudying severe long COVID to understand post-infectious disorders beyond COVID-19 – Nature Medicine
Conteúdos relacionados:
Review: Post-acute COVID-19 syndrome.
ESCMID rapid guidelines for assessment and management of long COVID.
ERS statement on Long COVID-19 follow-up.
Proposed subtypes of long-Covid and their respective potential therapies.
EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)
Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.
COVID-19 infections increase risk of heart conditions up to a year later, study finds.
Comentário do autor no Twitter (fio – clique para saber mais)
1/ HGE (https://t.co/VMUVMAo1bJ) position paper on #LongCOVID #PACS . By focusing on the most severe patients, w severe organ damage/dysfunction following mild/moderate #COVID19 – we will search for genetic and immunological mechanisms of disease https://t.co/dZQPEoNkhl pic.twitter.com/tgblk7oFQG
— Petter Brodin (@BrodinPetter) April 5, 2022
Recomendações da OMS para colaboração na resistência antimicrobiana.
8 Abr, 2022 | 21:40hStrategic framework for collaboration on antimicrobial resistance – World Health Organization
Conteúdos relacionados:
Four priority actions to slow the silent pandemic of antimicrobial resistance.
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Comentário no Twitter
#DYK: Drug resistant organisms are found in people, animals, food, plants and the environment.
That's why WHO works in collaboration with @FAO, @OIEAnimalHealth & @UNEP to address #AntimicrobialResistance https://t.co/enhUb1jg2g pic.twitter.com/9elCBspx4y— World Health Organization (WHO) (@WHO) April 6, 2022
Consenso de especialistas | Passo a passo da abordagem diagnóstica para pacientes com uveíte.
8 Abr, 2022 | 21:19hEstudo observacional sugere que a 4ª dose da vacina da Pfizer forneceu proteção adicional contra doença grave em pacientes com 60 anos de idade ou mais durante a onda da variante Ômicron em Israel.
8 Abr, 2022 | 21:11hProtection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine
Comentário: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (necessário cadastro gratuito)
Conteúdos relacionados:
Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.
U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Covid-19: Fourth vaccine doses—who needs them and why?
[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.
Comentário no Twitter
Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j— Eric Topol (@EricTopol) April 5, 2022
Estudo de coorte retrospectiva | Queda na efetividade das vacinas Pfizer e CoronaVac contra COVID-19 na Malásia.
8 Abr, 2022 | 21:08h
Comentário no Twitter
@ICR_NIH RECoVam's
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia in IJID.https://t.co/QwNSRQBKOq• Against infections, both wane after 3-5 months
• Against ICU admission, CoronaVac wane
• Against death, both retain considerable effectiveness— Dr Kalai Peariasamy (@drkalai61) March 22, 2022
Estudo de coorte | Taxas de incidência e desfechos clínicos da infecção por SARS-CoV-2 com as variantes Ômicron e Delta em crianças menores de 5 anos nos EUA.
8 Abr, 2022 | 17:27h
Comentário no Twitter
In this cohort study, the incidence rate of #SARSCoV2 infection with Omicron variant was 6 to 8 times that of Delta variant in children younger than 5 years, but severe clinical outcomes were less frequent than with Delta variant. https://t.co/UKiMEznXtX
— JAMA Pediatrics (@JAMAPediatrics) April 1, 2022
Estudo randomizado | Cabotegravir (injeções intramusculares a cada 8 semanas) na prevenção de HIV-1 em mulheres.
8 Abr, 2022 | 17:25hCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
FDA approves first injectable treatment for HIV pre-exposure prevention.
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.